解读美国糖尿病学会与欧洲糖尿病研究协会关于“以患者为中心的2型糖尿病高血糖管理方案”的立场声明  

A better comprehension of “Management of Hyperglycemia in Type 2 Diabetes:A Patient-Centered Approach—Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)”

作　　者：钱荣立[1,2] 

机构地区：[1]北京大学第一医院内分泌科 [2]北京大学糖尿病中心,100034

出　　处：《中国糖尿病杂志》2013年第1期5-6,共2页Chinese Journal of Diabetes

摘　　要：2012年4月同时发表在《Diabetes Care》和《Diabetology》上的美国糖尿病学会(ADA)和欧洲糖尿病研究协会(EASD)关于"以患者为中心的T2DM高血糖管理方案"的共识声明,第一,强调主要是针对T2DM的高血糖控制;第二,对血糖控制目标值,根据患者的自然病程、病情、伴发病以及年龄和预期寿命等因素作了灵活处理;第三,再次强调二甲双胍为一线用药;第四,更具体地讨论了各种胰岛素制剂、GLP-1、DPP-4抑制剂和受体激动剂的应用、疗效和利弊;第五,强调个体化治疗方案;第六,强调所有的患者都要接受针对血糖控制的糖尿病教育。Management of Hyperglycemia in Type 2 Diabetes： A Patient-Centered Approach -- Position Statement of the American Diabetes Association （ADA） and the European Association for the Study of Diabetes （EASD） was published in Diabetes Care and Diabetology in April this year. It, first, emphasizes the control of hyperglycemia in the treatment of T2DM; second, sets up the target of control of hyperglycemia flexibly according to natural course of disease, pathological condition, accompanied diseases, age, and life expectancy of the patients; third, once again emphasizes metformin for first-line use; fourth, more specifically discusses the applications, therapeutic effects, and advantages and disadvantages of various insulin preparations, GLP-1, DPP-4 inhibitors and GLP-1 receptor agonists; fifth, states the individualization treatment; and sixth, underlines that all patients should accept diabetes education aimed at hyperglycemia control.

关 键 词：美国糖尿病学会(ADA) 欧洲糖尿病研究协会(EASD) 高血糖控制 二甲双胍 糖尿病教育 

分 类 号：R587.1[医药卫生—内分泌]